These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38171391)

  • 1. A panel of hepatitis C virus glycoproteins for the characterization of antibody responses using antibodies with diverse recognition and neutralization patterns.
    Chumbe A; Grobben M; Capella-Pujol J; Koekkoek SM; Zon I; Slamanig S; Merat SJ; Beaumont T; Sliepen K; Schinkel J; van Gils MJ
    Virus Res; 2024 Mar; 341():199308. PubMed ID: 38171391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
    Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
    J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development.
    Salas JH; Urbanowicz RA; Guest JD; Frumento N; Figueroa A; Clark KE; Keck Z; Cowton VM; Cole SJ; Patel AH; Fuerst TR; Drummer HE; Major M; Tarr AW; Ball JK; Law M; Pierce BG; Foung SKH; Bailey JR
    Gastroenterology; 2022 Feb; 162(2):562-574. PubMed ID: 34655573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of the pseudoparticle system for standardized assessments of neutralizing antibodies against hepatitis C virus.
    Chumbe A; Urbanowicz RA; Sliepen K; Koekkoek SM; Molenkamp R; Tarr AW; Ball JK; Schinkel J; van Gils MJ
    J Gen Virol; 2022 Nov; 103(11):. PubMed ID: 36399377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.
    Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
    Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
    J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.
    Wasilewski LN; Ray SC; Bailey JR
    J Gen Virol; 2016 Nov; 97(11):2883-2893. PubMed ID: 27667373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.
    Ruwona TB; Giang E; Nieusma T; Law M
    J Virol; 2014 Sep; 88(18):10459-71. PubMed ID: 24965471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization.
    Pierce BG; Keck ZY; Wang R; Lau P; Garagusi K; Elkholy K; Toth EA; Urbanowicz RA; Guest JD; Agnihotri P; Kerzic MC; Marin A; Andrianov AK; Ball JK; Mariuzza RA; Fuerst TR; Foung SKH
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32878891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.
    Tarr AW; Urbanowicz RA; Hamed MR; Albecka A; McClure CP; Brown RJ; Irving WL; Dubuisson J; Ball JK
    J Virol; 2011 May; 85(9):4246-57. PubMed ID: 21325403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.
    Colbert MD; Flyak AI; Ogega CO; Kinchen VJ; Massaccesi G; Hernandez M; Davidson E; Doranz BJ; Cox AL; Crowe JE; Bailey JR
    J Virol; 2019 Jul; 93(14):. PubMed ID: 31068427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
    Swann RE; Cowton VM; Robinson MW; Cole SJ; Barclay ST; Mills PR; Thomson EC; McLauchlan J; Patel AH
    J Virol; 2016 May; 90(9):4530-4543. PubMed ID: 26912610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies.
    Stamataki Z; Coates S; Evans MJ; Wininger M; Crawford K; Dong C; Fong YL; Chien D; Abrignani S; Balfe P; Rice CM; McKeating JA; Houghton M
    Vaccine; 2007 Nov; 25(45):7773-84. PubMed ID: 17919789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp).
    Bailey JR; Urbanowicz RA; Ball JK; Law M; Foung SKH
    Methods Mol Biol; 2019; 1911():441-450. PubMed ID: 30593644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiplex flow cytometry-based assay to study the breadth of antibody responses against E1E2 glycoproteins of hepatitis C virus.
    Merat SJ; van de Berg D; Bru C; Yasuda E; Breij E; Kootstra N; Prins M; Molenkamp R; Bakker AQ; de Jong MD; Spits H; Schinkel J; Beaumont T
    J Immunol Methods; 2018 Mar; 454():15-26. PubMed ID: 28855105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
    Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
    J Virol; 2018 May; 92(9):. PubMed ID: 29467319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
    Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
    J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development.
    Chen F; Nagy K; Chavez D; Willis S; McBride R; Giang E; Honda A; Bukh J; Ordoukhanian P; Zhu J; Frey S; Lanford R; Law M
    Gastroenterology; 2020 Mar; 158(4):1058-1071.e6. PubMed ID: 31809725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of the human antibody response to the neutralization epitopes encompassing amino acids 313-327 and 432-443 of hepatitis C virus E1E2 glycoproteins.
    Liu R; Rao H; Wang J; Xie X; Jiang D; Pan X; Zhao P; Zhang H; Wei L
    PLoS One; 2013; 8(6):e66872. PubMed ID: 23826163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.